Sign in Subscribe
Coronaviruses

European Union's Top Drug Regulator Recommends Approval for Novavax's COVID-19 Vaccine

Strategic Insights

— 2 min read

The European Medicines Agency (EMA) has issued a recommendation for the approval of Novavax's COVID-19 vaccine for use in the European Union. This move comes after the World Health Organization granted emergency authorization for the vaccine in low-income countries. The EMA recommendation, which was made two days after the WHO's authorization, has been based on recent trials conducted in Mexico, the United States, and Britain, which showed a high efficacy rate of the vaccine in reducing symptomatic COVID-19 cases.

Key Takeaways:

  • The European Medicines Agency (EMA) has recommended approval for Novavax's COVID-19 vaccine, which has been shown to have a 90.4% efficacy in reducing symptomatic COVID-19 cases in a study published in the New England Journal of Medicine.
  • The EMA recommendation is based on trials conducted in Mexico, the United States, and Britain, where the vaccine showed high efficacy against the Alpha and Beta variants of the coronavirus.
  • The Novavax vaccine is expected to be the first protein-based COVID-19 vaccine in the EU, and its ability to be stored and shipped at normal refrigeration temperatures makes it a viable option for large-scale vaccinations.
  • The vaccine is expected to be approved for adults over the age of 18, and it would be the fifth vaccine to receive EMA authorization, after those from Pfizer, Moderna, AstraZeneca, and Johnson & Johnson.
  • The Novavax vaccine has been granted emergency authorization by the World Health Organization for use in low-income countries, and it is expected to make up a large chunk of the world's vaccine supply.
  • According to Dr. Mariangela Simao, WHO assistant director general for access to medicines, the authorization aims to increase access to vaccines in lower-income countries, where 41 countries have not yet vaccinated 10% of their populations, and 98 countries have not reached 40%.
  • The EMA noted that there is limited data on how the Novavax vaccine behaves against the more transmissible Delta and Omicron variants of the coronavirus.

Statistics:

  • 90.4% efficacy in reducing symptomatic COVID-19 cases in a study published in the New England Journal of Medicine (Mexico-U.S. study)
  • 89.7% efficacy in reducing symptomatic COVID-19 cases in a study published in the New England Journal of Medicine (British study)
  • 41 countries have not vaccinated 10% of their populations (as of WHO statement)
  • 98 countries have not reached 40% vaccination rate (as of WHO statement)
  • The Novavax vaccine is the ninth vaccine to be approved by the World Health Organization
  • The Novavax vaccine is expected to be the first protein-based COVID-19 vaccine in the EU

Sources:

  • "European Medicines Agency recommends approval for Novavax's COVID-19 vaccine" (EMA statement)
  • "WHO grants emergency authorization for Novavax COVID-19 vaccine in low-income countries" (WHO statement)
  • "Novavax COVID-19 vaccine shows 90.4% efficacy in reducing symptomatic cases in Mexican study" (New England Journal of Medicine publication)
  • "Novavax COVID-19 vaccine shows 89.7% efficacy in reducing symptomatic cases in British study" (New England Journal of Medicine publication)

Read more